NY-FLEXTRADE-SYSTEMS
20.2.2024 14:01:31 CET | Business Wire | Press release
FlexTrade Systems (@FlexTrade), a global leader in multi-asset execution and order management systems, and JonesTrading, a leading global equity brokerage & capital markets firm today announced the successful deployment of FlexOMS as the new sell-side trading platform for its equities and electronic trading businesses. The solution will also be the full-service technology platform for JonesTrading’s growing outsourced trading offering.
JonesTrading partners with over 1,500 institutions and hedge funds, providing a range of liquidity sources, electronic trading and execution management services globally. As part of its regular strategic reviews of the technology solutions and vendor relationships that serve its various business units, JonesTrading identified the need to replace its incumbent sell-side OMS solution during Q3 of 2023. Following a comprehensive evaluation of the available options in the market, the firm chose FlexTrade’s multi-asset sell-side trading order management solution, FlexOMS, as the optimal platform to expand upon their equities, outsourced, and electronic trading desks both now and in the future.
The project kicked off in 2023, with FlexOMS live and in production in record time, ultimately encompassing JonesTrading’s equities, electronic trading, and outsourced trading desk. Using FlexOMS’s open architecture and API-rich technology, the solution was also able to connect all of JonesTrading’s vital downstream systems, including reporting, accounting, best execution, and finance systems, within the allotted deadline.
Jack Garceau, Chief Technology Officer at JonesTrading noted: “Firstly, our aggressive timelines meant that we needed to work with a partner who understood our business and offered flexible yet powerful technology solutions to meet our requirements. That was essentially the baseline. Equally crucial in our decision was selecting a partner that could value-add in addition to the technology by offering the services and long-term relationships that we need to continue to build out our service offerings. To continue growing, FlexTrade was that reliable partner that could meet our business needs from a technology perspective and deliver in the contracted time frame that the project demanded.”
Rajiv Kedia, Principal & Associate Founder at FlexTrade Systems added: “We are delighted to welcome JonesTrading to the FlexOMS global client community and appreciate the confidence they placed in FlexTrade. It has been a pleasure working with the highly knowledgeable team at JonesTrading and we are happy to see this solution in place. It demonstrates clearly what can be achieved with a tight, synchronized approach between client and technology partner when implementing flexible, open OMS solutions. Our open-architecture, client-first approach has delivered cutting-edge trading technology and seamless straight-through processing to JonesTrading’s multiple business lines. We look forward to partnering further with JonesTrading to optimize and expand their use of FlexOMS to other business areas.”
About FlexTrade
FlexTrade Systems is the global leader in high-performance trading technology, including multi-asset execution and order management systems that span across equities, fixed income, foreign exchange, futures, and options. We’re recognized globally for our innovation lead by client-driven collaboration across order and execution management tools and solutions.
With a global presence in 45 countries, we work closely with both buy- and sell-side clients. Our team of over 500 dedicated software developers and industry specialists curate powerful, customized trading workflows across multiple asset classes. Our commitment to customer-centric innovation leads to breakthrough solutions that boost trading performance.
About JonesTrading
JonesTrading Institutional Services LLC is a leading global institutional trading broker dealer. Since 1975, JonesTrading's sole focus has been creating liquidity for institutional and corporate clients on an unconflicted basis. The ability to provide a secure trusted platform connecting a diverse group of market participants enables the firm to unlock liquidity, providing best-quality execution for larger and more complex trades. Member FINRA and SIPC.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240220754835/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release
Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit
Andersen Global udvider sin tilstedeværelse i Afrika med lanceringen af medlemsfirma i Cameroun26.4.2026 20:56:00 CEST | Pressemeddelelse
Andersen Global træder ind på det camerounske marked, idet Phoenix Advisory bliver medlemsfirma og overgår til Andersen-brandet. Andersen in Cameroun er et specialiseret rådgivningsfirma, der leverer strategiske, erhvervsmæssige, finansielle og operationelle rådgivningsydelser til organisationer i forskellige vækstfaser. Firmaet er grundlagt af fagfolk med erfaring fra store internationale organisationer og kombinerer et stærkt lokalt og centralafrikansk funderet kendskab til forretningsmæssige, juridiske og skattemæssige regler med en skræddersyet tilgang, der har til formål at skabe konkrete og målbare resultater for klienterne. "Overgangen til Andersen-brandet afspejler vores engagement i at vokse sammen med vores kunder og imødekomme stadig mere komplekse behov," udtalte administrerende partner Albert Désiré Zang. "Vi tror på, at langsigtet succes skabes gennem tillid, kvalitet og vedvarende support. At blive et medlemsfirma styrker vores evne til at levere gennemtænkte, bæredygtig
PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom